Neve
Antje Neve, Poing DE
Patent application number | Description | Published |
---|---|---|
20090201376 | Apparatus for Calibrating an Optical Camera and/or an Infrared Camera - An apparatus is provided for calibrating an optical camera and/or an infrared camera, in particular an infrared tele-camera, that is/are arranged in a motor vehicle and that has a checkered appearance with first and second fields. In order to make the known apparatus suitable for a plurality of camera systems, it is suggested that the first fields are heated or cooled. | 08-13-2009 |
Gerrit Richard Neve, Encinitas, CA US
Patent application number | Description | Published |
---|---|---|
20090244089 | APPARATUS AND METHOD FOR AUTOMATIC SCALING OF TICK MARKS - A computer readable storage medium includes executable instructions to calculate a default number of major tick marks as a function of a minimum distance between major tick marks and the length of a GUI control. A whole number of major tick marks that evenly divides a range of values to be mapped along the length of the GUI control is iteratively searched. A whole number of major tick marks is displayed along the length of the GUI control. The default number of major tick marks is the origin from which the search begins. | 10-01-2009 |
Jean Neve, Bruxelles BE
Patent application number | Description | Published |
---|---|---|
20110280940 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy - The invention relates to the medical field, more precisely in the field of anti-cancer treatment and treatment of Alzheimer's disease, Parkinson's disease or Pick's disease or for ameliorating symptoms of Down syndrome, providing newly synthesised multi-vanilloyl derivative compounds and their use in the treatment of said disorders. | 11-17-2011 |
Kim A. Neve, Portland, OR US
Patent application number | Description | Published |
---|---|---|
20090012179 | Use of Tyrphostins to Stimulate Neurite Outgrowth - Disclosed herein are several methods for promoting nerve regeneration. The methods include administering at least one tyrphostin, or a pharmaceutically acceptable salt thereof. In one non-limiting example, the tyrphostin is tyrphostin A9. These methods can be used to promote nerve growth in the central or peripheral nervous system. The methods are of use in treating neurodegenerative diseases, such as Parkinson's disease, or in treating the transaction of a partial or complete transaction of a nerve in the peripheral or central nervous system. | 01-08-2009 |
Richard Neve, Sandwich GB
Patent application number | Description | Published |
---|---|---|
20110098226 | Small molecular weight TNF receptor multimeric molecule - The present invention relates to a receptor molecule which binds to TNF comprising all or a functional portion of the extracellular domain (ECD) of two or more TNF-Rs linked via one or more polypeptide linkers. The receptor can further comprise a signal peptide of a secreted protein, such as the signal peptide of the extracellular domain of the TNF-R or the signal peptide of a cytokine. The invention also relates to isolated DNA encoding a receptor molecule which binds to TNF, comprising two or more sequences encoding all or a functional portion of the ECD of TNF-Rs linked via one or more sequences encoding a polypeptide linker. The invention further relates to a method of making a construct which expresses all or a functional portion of the ECD of two or more TNF-Rs linked via one or more polypeptide linkers and cells which express the construct. The invention also relates to a method of inhibiting the biological activity of TNF in a host comprising administering to the host an effective amount of a receptor molecule of the present invention. The invention further relates to receptor molecules which bind cytokines that bind to receptor molecules comprising more than one subunit. | 04-28-2011 |
Richard Neve, San Mateo, CA US
Patent application number | Description | Published |
---|---|---|
20090203051 | TARGETS IN BREAST CANCER FOR PROGNOSIS OR THERAPY - Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers. | 08-13-2009 |
20120077694 | TARGETS IN BREAST CANCER FOR PROGNOSIS OR THERAPY - Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers. | 03-29-2012 |
Richard M. Neve, San Mateo, CA US
Patent application number | Description | Published |
---|---|---|
20090011428 | Fluid Membrane-Based Ligand Display System for Live Cell Assays and Disease Diagnosis Applications - A supported membrane based, strategy for the presentation of soluble signaling molecules to living cells is described. In this system, the fluidity of the supported membrane enables localized enrichment of ligand density in a configuration reflecting cognate receptor distribution on the cell surface. Display of a ligand in non-fluid supported membranes produces significantly less cell adhesion and spreading, thus demonstrating that this technique provides a means to control functional soluble ligand exposure in a surface array format. Furthermore, this technique can be applied to tether natively membrane-bound signaling molecules such as ephrin A1 to a supported lipid bilayer. Such a surface can modulate the spreading behavior of metastatic human breast cancer cells displaying ligands and biomolecules of choice. The SLB microenvironment provides a versatile platform that can be tailored to controllably and functionally present a multitude of cell signaling events in a parallel surface array format. | 01-08-2009 |
20090318533 | Annexin A9 (ANXA9) Biomarker and Therapeutic Target in Epithelial Cancer - Amplification of the ANXA9 gene in human chromosomal region 1q21 in epithelial cancers indicates a likelihood of both in vivo drug resistance and metastasis, and serves as a biomarker indicating these aspects of the disease. ANXA9 can also serve as a therapeutic target. Interfering RNAs (iRNAs) (such as siRNA and miRNA) and shRNA adapted to inhibit ANXA9 expression, when formulated in a therapeutic composition, and delivered to cells of the tumor, function to treat the epithelial cancer. | 12-24-2009 |
20110183336 | Method to Predict Responsiveness of Breast Cancer to Polyamine-Type Chemotherapy - Methods of-identifying a basal or luminal phenotype of a cell, comprising detecting expression of one or more of a set of predictive biomarker genes or proteins that identify the cell as having a basal or luminal cancer subtype and compositions for treating identified basal or luminal cancers. | 07-28-2011 |
Soeren Neve, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20110144002 | Use of AMPs for Treatment of UTI/Cystitis - The present invention relates to methods for treating urinary tract infections, such as cystitis, with antimicrobial polypeptides polypeptides. | 06-16-2011 |
Sore Neve, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20090264300 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES - Disclosed is a method for obtaining a bifunctional complex comprising a molecule linked to a single stranded identifier oligonucleotide, wherein a nascent bifunctional complex comprising a chemical reaction site and a priming site for enzymatic addition of a tag is a) reacted at the chemical reaction site with one or more reactants, and b) reacted enzymatically at the priming site with one or more tag(s) identifying the reactant(s). | 10-22-2009 |
Soren Neve, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20110306750 | ANTIMICROBIAL PEPTIDE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 12-15-2011 |
20150031601 | Antimicrobial Peptide Variants and Polynucleotides Encoding Same - The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 01-29-2015 |
Søren Neve, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20110144008 | PEPTIDE AGONISTS OF GLP-1 ACTIVITY - Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders. | 06-16-2011 |
20110245165 | PEPTIDE AGONISTS OF GLP-1 ACTIVITY - Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders. | 10-06-2011 |
20130210722 | METHODS FOR USING PEPTIDE AGONISTS HAVING GLP-1 ACTIVITY - Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders. | 08-15-2013 |
Søren Neve, Kgs. Lyngby DK
Patent application number | Description | Published |
---|---|---|
20140336356 | PEPTIDE AGONISTS OF GLP-1 ACTIVITY - Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders. | 11-13-2014 |
Tommas Neve, Hadsten DK
Patent application number | Description | Published |
---|---|---|
20110034394 | COMPOSITION COMPRISING PROTEIN AND DISPERSE FAT - The present invention relates to a method for the manufacture of a composition comprising proteins and fats, said method providing a simple and non-expensive way of obtaining fat-containing proteinaceous products of high nutritional value that are easy to handle and at the same time possess high stability towards coalescence and oxidation. More particularly, a method is provided for the manufacture of a composition comprising protein and fat in disperse form, the method comprising the following steps: (i) providing a suspension having a pH value higher than 7.0, said suspension comprising water, proteinaceous material, fat, and optionally alkali; (ii) incubating the suspension from (i) at a temperature in the interval 50-150° C.; (iii) homogenizing the suspension from (ii) to form a dispersion; and (iv), if desired, subjecting the dispersion from (iii) to a subsequent treatment; wherein the proteinaceous material in step (i) comprises vegetable-based proteinaceous material, and/or yeast-based proteinaceous material; wherein the suspension in step (i) comprises at least 5% fat by weight of dry matter. The current invention also relates to the compositions obtained by the method and to compositions obtainable by the method of the invention and, further, to the use of these compositions. | 02-10-2011 |